• KalVista Anticipates Milestones in 2 HAE Treatment Candidates in Second Half of 2020
  • HAE International Translates Printable Emergency Card into 34 Languages
  • Cipla Given FDA Approval for Icatibant, Generic Version of Firazyr
  • National Survey Seeks to Assess Full Social, Economic Burdens of Rare Diseases in US
  • Preventive Takhzyro Reduces HAE Attacks Early in Treatment, Analysis Shows
  • Haegarda Safe, Effective in Older HAE Patients, Trial Analysis Shows 
  • Prophylactic Takhzyro Effective for Broad Range of HAE Patients, Study Suggests
  • Alexion Charitable Foundation Giving $1.1M to Assist Rare Disease Community During Pandemic
  • Ruconest More Cost-effective Than Other On-demand Treatments for HAE Attacks, Study Estimates
  • Garadacimab Reduces HAE Attacks Significantly, Preliminary Phase 2 Trial Results Show
  • Data Support Long-term Efficacy of Berotralstat in HAE, BioCryst Says
  • Coalition Will Address Racial Disparities in Rare Disease Communities